US5888477A
(en)
*
|
1993-01-29 |
1999-03-30 |
Aradigm Corporation |
Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
|
EP1607086A1
(en)
*
|
1993-01-29 |
2005-12-21 |
Aradigm Corporation |
Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
|
US6131567A
(en)
*
|
1993-01-29 |
2000-10-17 |
Aradigm Corporation |
Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
|
US6024090A
(en)
*
|
1993-01-29 |
2000-02-15 |
Aradigm Corporation |
Method of treating a diabetic patient by aerosolized administration of insulin lispro
|
DK72793D0
(da)
*
|
1993-06-21 |
1993-06-21 |
Novo Nordisk As |
Nyt produkt
|
US5461031A
(en)
*
|
1994-06-16 |
1995-10-24 |
Eli Lilly And Company |
Monomeric insulin analog formulations
|
US5547929A
(en)
*
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
AR002976A1
(es)
*
|
1995-03-31 |
1998-05-27 |
Lilly Co Eli |
Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
|
EP0835129B1
(en)
*
|
1995-06-30 |
2003-10-29 |
Novo Nordisk A/S |
Prevention of a disease having the characteristics of diabetes
|
BR9709845B1
(pt)
*
|
1996-06-20 |
2008-11-18 |
|
preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
|
DE69829953T2
(de)
*
|
1997-02-07 |
2006-03-02 |
Novo Nordisk A/S |
Kristallisation von proteinen
|
US5898067A
(en)
*
|
1997-02-07 |
1999-04-27 |
Novo Nordisk A/S |
Crystallization of proteins
|
AR012894A1
(es)
*
|
1997-06-13 |
2000-11-22 |
Lilly Co Eli |
Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
|
EP1283051B1
(en)
*
|
1997-06-13 |
2006-06-14 |
Eli Lilly And Company |
Stable insulin formulations
|
PL340255A1
(en)
*
|
1997-10-24 |
2001-01-29 |
Lilly Co Eli |
Non-dissolving insulin compositions
|
US6531448B1
(en)
*
|
1997-12-23 |
2003-03-11 |
Eli Lilly And Company |
Insoluble compositions for controlling blood glucose
|
US20010053761A1
(en)
*
|
1998-01-08 |
2001-12-20 |
Dimarchi Richard Dennis |
Method for administering aspb28-human insulin
|
US20040214747A1
(en)
*
|
1999-01-06 |
2004-10-28 |
Dimarchi Richard Dennis |
Method for administering monomeric insulin
|
US6624141B1
(en)
*
|
1999-03-17 |
2003-09-23 |
The Regents Of The University Of Michigan |
Protamine fragment compositions and methods of use
|
US7169889B1
(en)
*
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
EP1346726A4
(en)
*
|
2000-12-25 |
2004-09-15 |
Shiseido Co Ltd |
FRAGRANCE COMPOSITION STIMULATING THE SYMPATHETIC SYSTEM
|
EP1772464B1
(en)
*
|
2001-02-09 |
2009-08-12 |
Genentech, Inc. |
Methods of identifying indirect agonists of IGF-1
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6867183B2
(en)
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US6828305B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
*
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
WO2003020201A2
(en)
*
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
US7196059B2
(en)
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US7166571B2
(en)
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7312192B2
(en)
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US6913903B2
(en)
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
CN1571676A
(zh)
*
|
2001-10-19 |
2005-01-26 |
伊莱利利公司 |
Glp-1和胰岛素的双相混合物
|
AU2002346491A1
(en)
*
|
2001-12-19 |
2003-07-09 |
Eli Lilly And Company |
Crystalline compositions for controlling blood glucose
|
AU2003236521A1
(en)
*
|
2002-06-13 |
2003-12-31 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
US20060258561A1
(en)
*
|
2003-03-13 |
2006-11-16 |
Novo Nordisk A/S |
Novel NPH insulin preparations
|
WO2004111244A2
(en)
|
2003-06-17 |
2004-12-23 |
Sembiosys Genetics Inc. |
Methods for the production of insulin in plants
|
US20050054818A1
(en)
*
|
2003-07-02 |
2005-03-10 |
Brader Mark Laurence |
Crystalline compositions for controlling blood glucose
|
JP2007520441A
(ja)
*
|
2003-07-25 |
2007-07-26 |
コンジュシェム,インコーポレイティド |
持続性インスリン誘導体及びその方法
|
WO2005072803A1
(en)
*
|
2004-01-16 |
2005-08-11 |
Biodel, Inc. |
Sublingual drug delivery device
|
US20080096800A1
(en)
*
|
2004-03-12 |
2008-04-24 |
Biodel, Inc. |
Rapid mucosal gel or film insulin compositions
|
PT2319500E
(pt)
*
|
2004-03-12 |
2013-01-23 |
Biodel Inc |
Composições de distribuição de fármacos de actuação rápida
|
US20080090753A1
(en)
*
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
US20080085298A1
(en)
*
|
2004-03-12 |
2008-04-10 |
Biodel, Inc. |
Rapid Mucosal Gel or Film Insulin Compositions
|
WO2006014673A2
(en)
|
2004-07-19 |
2006-02-09 |
Nobex Corporation |
Insulin-oligomer conjugates, formulations and uses thereof
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
AU2005273968A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
|
US7884181B2
(en)
*
|
2004-10-05 |
2011-02-08 |
Novo Nordisk A/S |
Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
US8084420B2
(en)
*
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US7713929B2
(en)
*
|
2006-04-12 |
2010-05-11 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
CN100371346C
(zh)
*
|
2005-12-14 |
2008-02-27 |
浙江大学 |
人工合成胰岛素模拟肽及其应用
|
WO2007096431A1
(en)
*
|
2006-02-27 |
2007-08-30 |
Novo Nordisk A/S |
Insulin derivatives
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
US7718609B2
(en)
*
|
2006-04-12 |
2010-05-18 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
CN101062948B
(zh)
*
|
2006-04-29 |
2010-05-12 |
上海生物泰生命科学研究有限公司 |
单体速效胰岛素及其制法和用途
|
WO2008124522A2
(en)
*
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
ES2664822T3
(es)
|
2007-10-16 |
2018-04-23 |
Biocon Limited |
Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
|
CN101951957A
(zh)
*
|
2008-01-04 |
2011-01-19 |
百达尔公司 |
胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
|
WO2010028175A1
(en)
|
2008-09-08 |
2010-03-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulators of aldehyde dehydrogenase activity and methods of use thereof
|
JP2012506856A
(ja)
|
2008-10-28 |
2012-03-22 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
|
AU2010208305A1
(en)
|
2009-01-28 |
2011-09-08 |
Smartcells, Inc. |
Synthetic conjugates and uses thereof
|
MA33064B1
(fr)
*
|
2009-01-28 |
2012-02-01 |
Smartcells Inc |
Systemes à base de conjugués pour administration contrôlée de médicaments
|
MX2011008562A
(es)
|
2009-02-12 |
2011-09-09 |
Proyecto Biomedicina Cima Sl |
Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
JP2012520879A
(ja)
|
2009-03-20 |
2012-09-10 |
スマートセルズ・インコーポレイテツド |
末端官能基化コンジュゲートおよびその用途
|
HUP0900482A2
(en)
*
|
2009-08-03 |
2011-03-28 |
Cera Med Kft |
Pharmaceutical formulation for oral administration
|
AU2011282988A1
(en)
|
2010-07-28 |
2013-01-31 |
Smartcells, Inc. |
Recombinantly expressed insulin polypeptides and uses thereof
|
AU2011336896B2
(en)
*
|
2010-11-24 |
2015-12-24 |
Durect Corporation |
Biodegradable drug delivery composition
|
US20140011733A1
(en)
|
2011-01-20 |
2014-01-09 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
US10457659B2
(en)
|
2011-04-29 |
2019-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for increasing proliferation of adult salivary stem cells
|
CA2890048C
(en)
|
2012-12-03 |
2022-05-03 |
Merck Sharp & Dohme Corp. |
O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
|
KR20150135332A
(ko)
|
2013-03-14 |
2015-12-02 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
|
EP3052134B1
(en)
|
2013-10-04 |
2021-05-05 |
Merck Sharp & Dohme Corp. |
Glucose-responsive insulin conjugates
|
JP6564369B2
(ja)
|
2013-12-09 |
2019-08-21 |
デュレクト コーポレイション |
薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
|
MX2016008978A
(es)
*
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
BR112016016290A2
(pt)
|
2014-01-13 |
2017-10-03 |
Thermalin Diabetes Llc |
Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
DK3006045T3
(en)
|
2014-10-07 |
2017-07-17 |
Cyprumed Gmbh |
Pharmaceutical formulations for oral administration of peptide or protein drugs
|
WO2017163159A1
(en)
|
2016-03-21 |
2017-09-28 |
Wockhardt Limited |
Biphasic pharmaceutical composition of insulin human
|
JP6633777B2
(ja)
|
2017-08-24 |
2020-01-22 |
ノヴォ ノルディスク アー/エス |
Glp−1組成物及びその使用
|
US11110063B2
(en)
|
2017-08-25 |
2021-09-07 |
MAIA Pharmaceuticals, Inc. |
Storage stable sincalide formulations
|
WO2019125879A2
(en)
|
2017-12-18 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Conjugate based systems for controlled insulin delivery
|
EP3727424A4
(en)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
|
CN110063932A
(zh)
*
|
2019-04-12 |
2019-07-30 |
浙江大学 |
一种多肽蛋白类药物的缓释组合物制剂及其制备方法
|
US11318191B2
(en)
|
2020-02-18 |
2022-05-03 |
Novo Nordisk A/S |
GLP-1 compositions and uses thereof
|
WO2021202802A1
(en)
|
2020-03-31 |
2021-10-07 |
Protomer Technologies Inc. |
Conjugates for selective responsiveness to vicinal diols
|
PE20231948A1
(es)
|
2020-11-19 |
2023-12-05 |
Protomer Tech Inc |
Compuestos aromaticos que contienen boro y analogos de insulina
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|